The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1660
ISSUE1660
October 3, 2022
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
October 3, 2022 (Issue: 1660)
The 1.5% cream formulation of the Janus kinase
(JAK) inhibitor ruxolitinib (Opzelura – Incyte) has
been approved by the FDA for topical treatment of
nonsegmental vitiligo (NSV) in patients ≥12 years old.
Opzelura is the first product to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.